Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Micombi Can Be Differentiated from Other Combination Drugs: Mr Imahori of Astellas
July 20, 2009
- Fuji Keizai Predicts 4% Increase in OTC Anti-Obesity Drugs in 2009
July 20, 2009
- Higher Dosage Approved for Cravit: Daiichi Sankyo
July 20, 2009
- Sales of Class 1 OTC Drugs Down due to New Marketing System
July 20, 2009
- New Class 1 OTC Drugs Get Off to Flying Start: Taisho
July 20, 2009
- R&D NEWS IN BRIEF
July 20, 2009
- Japan Biotechnology Conference Kicked Off by 20 Biotech Firms
July 20, 2009
- ASCO 2009 Highlight Seminar by the Matson Jack Group
July 20, 2009
- Pfizer Discontinues PIII Trial of Sutent in Metastatic CRC
July 20, 2009
- GENERICS NEWS IN BRIEF
July 20, 2009
- Survey on Generics of Anticancer Drugs Shows Gaps between Generic Firms and Healthcare Professionals
July 20, 2009
- Anplag to Be Major Target for Generic NHI Price Listing in November
July 20, 2009
- REGULATORY NEWS IN BRIEF
July 20, 2009
- Nissui Pharma. to Market Switch OTC Version of Epadel from Mochida
July 13, 2009
- JSGM Presents Proposals to Promote Use of Generics
July 13, 2009
- Korosho to Inspect Generics Containing 5 More APIs
July 13, 2009
- Lasting Decreases in BP Obtained with Telmisartan + Amlodipine
July 13, 2009
- Concrete Reasons for Lack of Enthusiasm about Use of Generics to Be Determined
July 13, 2009
- R&D NEWS IN BRIEF
July 13, 2009
- Biosimilars Will also Struggle in Japan: Datamonitor
July 13, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…